ArticleiScience2024
Long COVID across SARS-CoV-2 variants, lineages, and sublineages.
Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Characteristics, all-cause healthcare resource utilisation, and costs among high-risk adults with long COVID during Omicron predominance, 2022-2023: a retrospective cohort study using UK primary care data.BMC health services research · 2026Article
- Comparison of SARS-CoV-2 variant pathogenicity in a long-COVID Syrian hamster model.Virus research · 2026Article
- Computational proteomics to enhance personalized treatment of COVID-19 and Long COVID.Clinical proteomics · 2026Review
- A narrative review of SARS-CoV-2 variants and long COVID.Journal of thoracic disease · 2026Review
- SARS-CoV-2 spike protein expression drives post-acute coagulopathy.Journal of virology · 2026Article
- Characterization of post-acute multi-organ sequelae following SARS-CoV-2 Infection in the Delta and Omicron Eras in a highly boosted population.BMC global and public health · 2026Article
- Early clinical and laboratory markers associated with post-COVID respiratory syndrome: A retrospective analysis.PloS one · 2026Article
- A retrospective cohort study of viral and sociodemographic determinants of long COVID among Idaho veterans.Frontiers in public health · 2026Article
- Lingering echoes of SARS-CoV-2: mechanistic insights and management of long COVID syndrome.Inflammopharmacology · 2026Review
- Prevalence and characterization of post-acute sequelae of SARS-CoV-2 infection (PASC) in Rwanda.IJID regions · 2025Article
- Associations Between APOE Polymorphisms, Neurological Symptoms, and Cognitive Assessments in Long COVID Patients: An Analysis of SNPs rs7412 and rs429358.Molecular neurobiology · 2025Article
- Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study.Nature communications · 2025Article
- Co-occurrence of memory impairment and fatigue distinguishes post COVID from pandemic-related health effects in the 4-year CON-VINCE cohort study.Scientific reports · 2025Article
- Age-Related Changes in the Clinical Picture of Long COVID.Journal of the American Geriatrics Society · 2025Article
- Long COVID-19: A Concept Analysis.Infectious disease reports · 2025Article
- Review
- Adult Long Coronavirus Disease 2019: Definition, Prevalence Pathophysiology, and Clinical Manifestations.Infectious disease clinics of North America · 2025Review
- Review
- Living with Long COVID in a Southern State: A Comparison of Black and White Residents of North Carolina.International journal of environmental research and public health · 2025Article
- Burden of acute and long-term COVID-19: a nationwide study in Bahrain.Frontiers in public health · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This prospective study aimed to determine the prevalence of long COVID in patients hospitalized for SARS-CoV-2 infection from March 2020 to July 2022 and assess the impact of different viral lineages. A total of 2,524 patients were followed up for 12 months, with persistent symptoms reported in 35.2% at one month, decreasing thereafter. Omicron variant patients initially showed higher symptom intensity, but this trend diminished over time. Certain viral lineages, notably Delta lineages AY.126 and AY.43, and Omicron sublineages BA.1.17, BA.2.56, and BA.5.1, consistently correlated with more severe symptoms. Overall, long COVID prevalence and severity were similar across SARS-CoV-2 variants. Specific lineages may influence post-COVID sequelae persistence and severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.